Clinical trial registry record

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 9, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02399072
Last registry update
August 9, 2019
Status
Terminated
Phase
Phase not reported
Sponsor
Hoffmann-La Roche
Enrollment
202
Countries
United States, Argentina, Australia, Brazil, Canada, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
202
Population
ALL · 50 Years
Duration
2015-03-30 to 2018-02-08
Intervention
No intervention
Comparator
Not reported
Outcomes measured
Mean Change from Baseline in the GA Area as Assessed by Fundus Autofluorescence (FAF) up to Month 60 — Baseline up to M…; Change from Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy S…; Change from Baseline in BCVA Score as Assessed by ETDRS Chart Under Low Luminance Conditions up to Month 60 — Baseline…; Change from Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Cards or Radn…; Change from Baseline in Monocular Reading Speed as Assessed by MNRead Cards or Radner Reading Cards up to Month 60 — Ba…; Change from Baseline in Binocular Critical Print Size as Assessed by MNRead Cards or Radner Reading Cards up to Month 6…; Change from Baseline in Monocular Critical Print Size as Assessed by MNRead Cards or Radner Reading Cards up to Month 6…; Change from Baseline in Near Activity Subscale as Assessed by National Eye Institute Visual Functioning Questionnaire 2…; Change from Baseline in Distance Activity Subscale as Assessed by NEI VFQ-25 up to Month 60 — Baseline up to Month 60; Change from Baseline in Composite Scores as Assessed by NEI VFQ-25 up to Month 60 — Baseline up to Month 60; Change from Baseline in Functional Reading Independence Score up to Month 60 — Baseline up to Month 60; Percentage of Participants With Medical Events — Baseline up to Month 60; Percentage of Participants With Ocular Events — Baseline up to Month 60
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.